Details of the Drug

General Information of Drug (ID: DMAL4G0)

Drug Name

Flurazepam

Synonyms

Dalmadorm; Dalmane; Felison; Felmane; Flunox; Flurazepamum; Insumin; Noctosom; Paxane; Somnol; Stauroderm; Valdorm; Flurazepam HCL; Flurazepam hydrochloride; Dalmadorm (TN); Dalmane (TN); Dalmane-R; Flurazepamum [INN-Latin]; Insumin (TN); Flurazepam (JP15/INN); Flurazepam [INN:BAN:JAN]; Ro-5-6901/3; 2H-1,4-Benzodiazepin-2-one,7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-, dihydrochloride; 7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1H-1,4-benzodiazepin-2(3H)-one; 7-Chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-1-(2-diethylaminoethyl)-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one

Indication

Disease Entry	ICD 11	Status	REF
Insomnia	7A00-7A0Z	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Hypnotics and Sedatives

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

387.9

Logarithm of the Partition Coefficient (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Bioavailability: 83% of drug becomes completely available to its intended biological destination(s) [3]
Elimination: 0.1% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 2.3 hours [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.10491 micromolar/kg/day [5]
Water Solubility: The ability of drug to dissolve in water is measured as 500 mg/mL [2]

Chemical Identifiers

Formula: C21H23ClFN3O
IUPAC Name: 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one
Canonical SMILES: CCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F
InChI: InChI=1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3
InChIKey: SAADBVWGJQAEFS-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3393
ChEBI ID: CHEBI:5128
CAS Number: 17617-23-1
DrugBank ID: DB00690
TTD ID: D08XFV
VARIDT ID: DR00570
INTEDE ID: DR0728
ACDINA ID: D00286

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Translocator protein (TSPO)	TTPTXIN	TSPO_HUMAN	Modulator	[6]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[7]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Flurazepam (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Altered absorption of Flurazepam due to GI dynamics variation caused by Sodium bicarbonate.	Acidosis [5C73]	[8]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Flurazepam caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[9]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Flurazepam and Oliceridine.	Acute pain [MG31]	[10]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Flurazepam caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[11]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Flurazepam caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[12]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Flurazepam caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[12]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Flurazepam caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[13]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Flurazepam caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[14]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Flurazepam and Dihydrocodeine.	Chronic pain [MG30]	[15]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Flurazepam and Olopatadine.	Conjunctiva disorder [9A60]	[16]
Propofol	DMB4OLE	Moderate	Additive cardiorespiratory depression effects by the combination of Flurazepam and Propofol.	Corneal disease [9A76-9A78]	[17]
Alfentanil	DMVO0UB	Major	Additive CNS depression effects by the combination of Flurazepam and Alfentanil.	Corneal disease [9A76-9A78]	[10]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Flurazepam and Remifentanil.	Corneal disease [9A76-9A78]	[10]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Flurazepam and Ethanol.	Cystitis [GC00]	[18]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Flurazepam caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[19]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Flurazepam caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[20]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Flurazepam and Esketamine.	Depression [6A70-6A7Z]	[21]
SODIUM CITRATE	DMHPD2Y	Minor	Altered absorption of Flurazepam due to GI dynamics variation caused by SODIUM CITRATE.	Discovery agent [N.A.]	[8]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Flurazepam caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Flurazepam caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Flurazepam caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[24]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Flurazepam caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[9]
Ethotoin	DMXWOCP	Moderate	Increased metabolism of Flurazepam caused by Ethotoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[24]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Flurazepam caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[25]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Flurazepam caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[26]
Rifampin	DMA8J1G	Minor	Increased metabolism of Flurazepam caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[27]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Flurazepam caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Flurazepam caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Didanosine	DMI2QPE	Minor	Altered absorption of Flurazepam due to GI dynamics variation caused by Didanosine.	Human immunodeficiency virus disease [1C60-1C62]	[8]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Flurazepam caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Probenecid	DMMFWOJ	Minor	Decreased metabolism of Flurazepam caused by Probenecid.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[30]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Flurazepam caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[31]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Flurazepam caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[9]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Flurazepam caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[32]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Flurazepam caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[9]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Flurazepam caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[33]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Flurazepam caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[34]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Flurazepam and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[35]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Flurazepam and Lasmiditan.	Migraine [8A80]	[36]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Flurazepam and Flibanserin.	Mood disorder [6A60-6E23]	[37]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Flurazepam and Thalidomide.	Multiple myeloma [2A83]	[38]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Flurazepam caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[9]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Flurazepam caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[39]
Modafinil	DMYILBE	Minor	Increased metabolism of Flurazepam caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[40]
Teduglutide	DMYOAKS	Moderate	Altered absorption of Flurazepam caused by Teduglutide.	Neonatal malabsorption syndrome [KB89]	[41]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Flurazepam and Levomethadyl Acetate.	Opioid use disorder [6C43]	[15]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Flurazepam and Apraclonidine.	Optic nerve disorder [9C40]	[42]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Flurazepam caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[43]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Flurazepam and Oxymorphone.	Pain [MG30-MG3Z]	[10]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Flurazepam and Levorphanol.	Pain [MG30-MG3Z]	[10]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Flurazepam and Dezocine.	Pain [MG30-MG3Z]	[10]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Flurazepam and Nalbuphine.	Pain [MG30-MG3Z]	[10]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Flurazepam and Buprenorphine.	Pain [MG30-MG3Z]	[44]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Flurazepam and Hydrocodone.	Pain [MG30-MG3Z]	[10]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Flurazepam caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[45]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Flurazepam caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[46]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Flurazepam caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[47]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Flurazepam caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[48]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Flurazepam and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[49]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Flurazepam and Fentanyl.	Sensation disturbance [MB40]	[10]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Flurazepam caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[50]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Flurazepam caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[9]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Flurazepam caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[21]
Armodafinil	DMGB035	Minor	Increased metabolism of Flurazepam caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[40]
LEE011	DMMX75K	Moderate	Decreased metabolism of Flurazepam caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[51]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Flurazepam caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[9]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Flurazepam and Tizanidine.	Tonus and reflex abnormality [MB47]	[52]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Flurazepam and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[49]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Flurazepam and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[49]
Amiodarone	DMUTEX3	Minor	Potentiate the pharmacologic effects by the combination of Flurazepam and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[53]
-----------


⏷ Show the Full List of 70 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
FD&C red no. 3	E00629	Not Available	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Flurazepam 15 mg capsule	15 mg	Oral Capsule	Oral
Flurazepam 30 mg capsule	30 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7188).
2	BDDCS applied to over 900 drugs
3	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7	Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3.
8	Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35. [PMID: 19188]
9	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
11	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
12	Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
13	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
14	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
15	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
16	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
17	Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
18	Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3. [PMID: 6789361]
19	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
20	Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS "Coadministration of nefazodone and benzodiazepines: 2. a pharmacokinetic interaction study with triazolam." J Clin Psychopharmacol 15 (1995): 320-6. [PMID: 8830062]
21	Cerner Multum, Inc. "Australian Product Information.".
22	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
23	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
24	Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183]
25	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
26	Ochs HR, Greenblatt DJ, Knuchel M "Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation." Br J Clin Pharmacol 16 (1983): 743-6. [PMID: 6140941]
27	Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ "Diazepam interaction with antituberculosis drugs." Clin Pharmacol Ther 29 (1981): 671-8. [PMID: 7214796]
28	Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
29	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
30	Abernethy DR, Greenblatt DJ, Ameer B, Shader RI "Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation." J Pharmacol Exp Ther 234 (1985): 345-9. [PMID: 4020675]
31	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
32	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
33	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
34	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
35	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
36	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
37	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
38	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
39	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
40	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
41	Product Information. Gattex (teduglutide). NPS Pharmaceuticals, Bedminster, NJ.
42	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
43	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
44	Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
45	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
46	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
47	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
48	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
49	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
50	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
51	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
52	Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
53	Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600]